Earnings Call Summary | Alpha Teknova(TKNO.US) Q1 2024 Earnings Conference
Earnings Call Summary | Alpha Teknova(TKNO.US) Q1 2024 Earnings Conference
The following is a summary of the Alpha Teknova, Inc. (TKNO) Q1 2024 Earnings Call Transcript:
以下是Alpha Teknova, Inc.（TKNO）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Alpha Teknova's Q1 2024 revenue showed a marginal 2% growth to $9.3 million over the previous year, with a notable 7% increase in Clinical Solutions.
The company's gross profit for Q1 2024 was $2.2 million with a gross margin of 23.8%, slightly down from 26.6% in Q1 2023 due to increased overheads.
The net loss for Q1 2024 narrowed to $8.1 million or $0.20 per diluted share from $8.8 million or $0.31 per diluted share in Q1 2023.
Alpha Teknova2024年第一季度的收入比上年略有增長2％，達到930萬美元，臨床解決方案顯著增長了7％。
由於管理費用增加，該公司2024年第一季度的毛利潤爲220萬美元，毛利率爲23.8％，略低於2023年第一季度的26.6％。
2024年第一季度的淨虧損從2023年第一季度的880萬美元或攤薄每股虧損0.31美元縮小至810萬美元，攤薄每股虧損0.20美元。
Business Progress:
業務進展：
Alpha Teknova started 2024 strong, focusing on producing critical reagents for the life sciences industry to expedite the introduction of innovative therapies and diagnostics.
Significant growth in work orders was seen in the new facility, accompanied by successful product launches of AAV-Tek AAV Stabilizer and Build-Tek.
The company notes increased interaction with customers and anticipates continuous improvement in gross margins and revenue.
The company also showcased growth in customer base, particularly in Clinical Solutions and Lab Essentials, giving an optimistic outlook for the future.
Alpha Teknova在2024年開局表現強勁，專注於爲生命科學行業生產關鍵試劑，以加快創新療法和診斷的引入。
新工廠的工單大幅增長，同時成功推出了AAV-Tek AAV穩定器和Build-Tek的產品。
該公司注意到與客戶的互動有所增加，並預計毛利率和收入將持續改善。
該公司還展示了客戶群的增長，特別是在臨床解決方案和實驗室必需品方面，對未來展望持樂觀態度。
More details: Alpha Teknova IR
更多詳情： 阿爾法 Teknova 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。